Begin main content

Erbitux for Left Sided Metastatic Colorectal Cancer – Details

Project Number pCODR 10128
Brand Name Erbitux
Generic Name Cetuximab
Strength 2 mg/mL
Tumour Type Gastrointestinal
Indication Left Sided Metastatic Colorectal Cancer
Funding Request For the first-line treatment of RAS wild-type metastatic colorectalcarcinoma (mCRC) patients with left sided primary tumours
Review Status Pending
Pre Noc Submission No
NOC Date September 9, 2005
Manufacturer Eli Lilly Canada Inc.
Submitter Eli Lilly Canada Inc.
Submission Date (Target Date) February 15, 2018
Submission Type New Indication
Prioritization Requested
Stakeholder Input Deadline (target date based on target submission date) ‡ March 2, 2018
Clarification The Submitter notified pCODR that they will be unable to submit by their original target date and an updated target submission date has been provided.
Check-point meeting (target date)
pERC Meeting (target date)
Initial Recommendation Issued (target date)
Feedback Deadline (target date) ‡
pERC Reconsideration Meeting (target date)
Final Recommendation Issued (target date)
Notification to Implement Issued

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.